<div id="readability-page-1"><p><span>Heron Therapeutics (NASDAQ:HRTX - Get Free Report)</span> was upgraded by stock analysts at Zacks Research to a &#34;strong sell&#34; rating in a research note issued to investors on Tuesday,Zacks.com reports.</p><p>HRTX has been the topic of several other reports. HC Wainwright started coverage on shares of Heron Therapeutics in a report on Monday, June 9th. They issued a &#34;buy&#34; rating and a $6.00 price objective on the stock. Needham &amp; Company LLC decreased their price objective on shares of Heron Therapeutics from $4.00 to $3.00 and set a &#34;buy&#34; rating on the stock in a report on Friday, August 8th. Finally, Wall Street Zen downgraded shares of Heron Therapeutics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, August 9th.</p><div><p><span></span><span>Get <strong>Heron Therapeutics</strong> alerts:</span></p></div><p><b>Check Out Our Latest Report on HRTX</b></p><h2>Heron Therapeutics Trading Down 3.6%</h2><p>Shares of HRTX opened at $1.35 on Tuesday. The company has a market cap of $206.94 million, a price-to-earnings ratio of -67.50 and a beta of 1.15. Heron Therapeutics has a 1-year low of $1.04 and a 1-year high of $2.68. The company's fifty day simple moving average is $1.94 and its 200 day simple moving average is $2.00. </p><p>Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last issued its earnings results on Friday, August 8th. The biotechnology company reported ($0.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.01). The company had revenue of $37.20 million for the quarter, compared to analyst estimates of $38.08 million.  As a group, research analysts forecast that  Heron Therapeutics will post -0.13 earnings per share for the current year. </p><h2>Insider Activity</h2><p>In other news, major shareholder Rubric Capital Management Lp acquired 2,387,225 shares of the business's stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average price of $1.50 per share, with a total value of $3,580,837.50. Following the completion of the transaction, the insider directly owned 29,100,728 shares of the company's stock, valued at $43,651,092. This trade represents a 8.94% increase in their position. The acquisition was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through the SEC website. Also, Director Adam Morgan acquired 1,766,546 shares of the business's stock in a transaction that occurred on Friday, August 8th. The shares were purchased at an average cost of $1.50 per share, with a total value of $2,649,819.00. Following the transaction, the director directly owned 8,753,290 shares of the company's stock, valued at $13,129,935. This trade represents a 25.28% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own  5.86% of the company's stock. </p><h2>Institutional Investors Weigh In On Heron Therapeutics</h2><p>Institutional investors and hedge funds have recently bought and sold shares of the company. Raymond James Financial Inc. bought a new stake in  Heron Therapeutics during the fourth quarter worth about $208,000.  AIGH Capital Management LLC bought a new stake in  Heron Therapeutics during the first quarter worth about $6,112,000.  Jefferies Financial Group Inc. bought a new stake in  Heron Therapeutics during the first quarter worth about $710,000.  Palisade Capital Management LP lifted its position in  Heron Therapeutics by 34.7% during the first quarter. Palisade Capital Management LP now owns 5,286,931 shares of the biotechnology company's stock worth $11,631,000 after purchasing an additional 1,360,542 shares during the period.  Finally, Point72 Asset Management L.P. bought a new position in shares of  Heron Therapeutics in the fourth quarter worth about $4,706,000. Institutional investors own  80.01% of the company's stock. </p><h2>Heron Therapeutics Company Profile</h2> (Get Free Report)<p>Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Heron Therapeutics</li><li>Top Biotech Stocks: Exploring Innovation Opportunities</li><li>How AEP Became a Critical AI Infrastructure Play</li><li>Golden Cross Stocks: Pattern, Examples and Charts </li><li>How Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go?</li><li>Stock Market Upgrades: What Are They?</li><li>Mercury Systems Up 27%: Financials Send Investors a Clear Signal</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Heron Therapeutics Right Now?</h2><p>Before you consider Heron Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Heron Therapeutics wasn't on the list.</p><p>While Heron Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

HRTX

<p>Zacks Research has downgraded Heron Therapeutics (NASDAQ:HRTX) to a "strong sell" rating. The stock opened at $1.35, with a market cap of $206.94 million. Recent earnings showed a loss of $0.02 per share, missing estimates. Major shareholders have increased their stakes, with Rubric Capital acquiring over 2.3 million shares. Institutional investors hold 80.01% of the company. Analysts forecast a loss of $0.13 per share for the current year.</p>

Heron Therapeutics (NASDAQ:HRTX) Rating Increased to Strong Sell at Zacks Research